Trial Profile
Phase 1 Study of ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 May 2023
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Acronyms RaSuRE
- 03 May 2023 Status changed from recruiting to completed.
- 19 Oct 2020 Planned End Date changed from 1 Jul 2019 to 31 Dec 2021.
- 19 Oct 2020 Planned primary completion date changed from 1 Jul 2019 to 31 Dec 2021.